4.6 Review

Cell Reprogramming to Model Huntington's Disease: A Comprehensive Review

Journal

CELLS
Volume 10, Issue 7, Pages -

Publisher

MDPI
DOI: 10.3390/cells10071565

Keywords

cell reprogramming; pluripotent stem cells; direct cell reprogramming; disease modelling; Huntington's disease; striatal differentiation

Categories

Ask authors/readers for more resources

Huntington's disease is a neurodegenerative disorder characterized by the progressive decline of motor, cognitive, and psychiatric functions. Cell reprogramming technologies offer a revolutionary approach for modeling and investigating neurological conditions, including HD, with the potential for new therapeutic targets and drug screening. This review discusses the use of cell reprogramming to study HD and recent advancements in the field that hold promise for future treatments.
Huntington's disease (HD) is a neurodegenerative disorder characterized by the progressive decline of motor, cognitive, and psychiatric functions. HD results from an autosomal dominant mutation that causes a trinucleotide CAG repeat expansion and the production of mutant Huntingtin protein (mHTT). This results in the initial selective and progressive loss of medium spiny neurons (MSNs) in the striatum before progressing to involve the whole brain. There are currently no effective treatments to prevent or delay the progression of HD as knowledge into the mechanisms driving the selective degeneration of MSNs has been hindered by a lack of access to live neurons from individuals with HD. The invention of cell reprogramming provides a revolutionary technique for the study, and potential treatment, of neurological conditions. Cell reprogramming technologies allow for the generation of live disease-affected neurons from patients with neurological conditions, becoming a primary technique for modelling these conditions in vitro. The ability to generate HD-affected neurons has widespread applications for investigating the pathogenesis of HD, the identification of new therapeutic targets, and for high-throughput drug screening. Cell reprogramming also offers a potential autologous source of cells for HD cell replacement therapy. This review provides a comprehensive analysis of the use of cell reprogramming to model HD and a discussion on recent advancements in cell reprogramming technologies that will benefit the HD field.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available